Diamond v. Chakrabarty

Diamond v. Chakrabarty. This landmark 1980 decision by the Supreme Court of the United States established that a live, human-made microorganism is patentable subject matter under United States patent law. The ruling, delivered by a narrow 5-4 majority, centered on a genetically engineered bacterium capable of breaking down crude oil, created by microbiologist Ananda Chakrabarty. The case fundamentally expanded the scope of patentable inventions to include novel life forms, directly fueling the growth of the biotechnology industry in the United States.

Background and legal context

The case originated from a patent application filed by Dr. Ananda Chakrabarty, a researcher working for the General Electric Company. Chakrabarty had developed a novel strain of the bacterium Pseudomonas through genetic engineering techniques, specifically using plasmid transfer, which gave it the unique ability to digest multiple components of crude oil. His patent claims included not only the process for creating the bacterium but also the bacterium itself. The United States Patent and Trademark Office (USPTO) examiner, under the direction of Sidney A. Diamond, the Commissioner of Patents, rejected the claims for the living organism, arguing that living things were not patentable subject matter under Title 35 of the United States Code. Chakrabarty appealed this decision to the United States Court of Customs and Patent Appeals (CCPA), which reversed the USPTO, holding that the microorganism was a non-naturally occurring manufacture or composition of matter. Commissioner Diamond then appealed the CCPA's ruling to the Supreme Court of the United States, setting the stage for a definitive legal judgment.

Supreme Court decision

On June 16, 1980, the Supreme Court of the United States affirmed the judgment of the United States Court of Customs and Patent Appeals in a 5-4 vote, ruling in favor of Chakrabarty. The Court held that the genetically modified bacterium constituted a patentable "manufacture" or "composition of matter" under Section 101 of the Patent Act. The decision was authored by Chief Justice Warren E. Burger and joined by Justices Potter Stewart, Harry Blackmun, William Rehnquist, and John Paul Stevens. The central legal question was whether the Patent Act's language, which dates to the Patent Act of 1793 and was later codified in the Patent Act of 1952, was intended by Congress to include living organisms engineered by human ingenuity.

Majority opinion

Chief Justice Warren E. Burger delivered the opinion of the Court, focusing on a broad, literal interpretation of the statutory language. The opinion emphasized that the relevant Patent Act language—"any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof"—was expansive and intended to include "anything under the sun that is made by man." Burger reasoned that Chakrabarty's bacterium was a non-naturally occurring product of human ingenuity, with a distinctive name, character, and use. The Court distinguished this creation from a naturally occurring organism, noting that the patent claims were not directed to a hitherto unknown natural phenomenon but to a non-naturally occurring manufacture or composition of matter with a new and utility derived from human intervention. The majority rejected the argument that the Congress or the Plant Patent Act of 1930 had implicitly excluded living organisms from patentability, stating that legislative silence did not constitute an exclusion.

Dissenting opinion

Justice William J. Brennan Jr. authored a dissenting opinion, joined by Justices Byron White, Thurgood Marshall, and Lewis F. Powell Jr.. The dissent argued that the Congress had not intended for living organisms to be included within patentable subject matter. Brennan pointed to the specific, later-enacted Plant Patent Act of 1930 and the Plant Variety Protection Act of 1970, which granted limited patent-like protections to certain plants, as evidence that Congress had considered the issue of living matter and had chosen to act with narrow, specific statutes. The dissent contended that the Court's broad ruling improperly usurped the legislative function, arguing that such a significant expansion of patent law—into the realm of life itself—should be determined by the elected representatives in Congress after full study and public debate, rather than by judicial interpretation of a centuries-old statute.

Impact and legacy

The decision in this case had an immediate and profound impact, providing the legal certainty needed for massive investment in the nascent field of biotechnology. It is widely credited with launching the biotechnology industry by assuring companies like Genentech and Amgen that their investments in genetically engineered products, from pharmaceuticals to agricultural biotechnology, could be protected by utility patents. The ruling paved the way for the patenting of other life forms, including genetically modified mice such as the Oncomouse, cell lines, and genes themselves. The legal precedent continues to influence contentious debates over the ethics and boundaries of patent law in areas like stem cell research and synthetic biology, while its core holding remains a cornerstone of intellectual property protection for biological inventions in the United States. Category:United States Supreme Court cases Category:United States patent case law Category:1980 in United States case law